RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce the first patient has been successfully dosed with L-DOS47, vinorelbine and cisplatin in its Phase IIB, open-label, randomized study in metastatic lung adenocarcinoma […]
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with the Moffitt Cancer Center (“Moffitt”), a poster entitled “Improving survival in pancreatic cancer using Doxorubicin in combination with L-DOS47” will […]
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer today provides an update on the Company’s s Clinical Development and Strategic plans. 20190211-HBP-Press-Release-Clinical-Development-and-Strategic-Update-1.pdf
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors. The Board has accepted the resignation of Dr. Marek Orlowski as a director of the Company. In […]
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a final tranche of a private placement financing for gross proceeds of CAD348,000. 20181228-HBP-Press-Release-Closes-Private-Placement-SEDAR.pdf
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a third tranche of a private placement financing for gross proceeds of CAD700,800. 20181221-HBP-Press-Release-Closes-Private-Placement-SEDAR.pdf
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a second tranche of a private placement financing for gross proceeds of CAD342,000. The Company expects to complete a third tranche of […]
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2019 ending October 31, 2018. HELIX-1Q2019-PressRelease-FINAL.pdf
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a first tranche of a private placement financing for gross proceeds of CAD871,200. The Company expects to complete a second tranche of […]